Published in Br J Pharmacol on July 01, 2012
New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2. Br J Pharmacol (2013) 1.43
The drug-target residence time model: a 10-year retrospective. Nat Rev Drug Discov (2015) 1.13
Ligand-dependent activation and deactivation of the human adenosine A(2A) receptor. J Am Chem Soc (2013) 1.02
Protein conformational plasticity and complex ligand-binding kinetics explored by atomistic simulations and Markov models. Nat Commun (2015) 0.99
The role of kinetic context in apparent biased agonism at GPCRs. Nat Commun (2016) 0.98
Insulin-increased L-arginine transport requires A(2A) adenosine receptors activation in human umbilical vein endothelium. PLoS One (2012) 0.91
Chemical, target, and bioactive properties of allosteric modulation. PLoS Comput Biol (2014) 0.91
Pharmacology and structure of isolated conformations of the adenosine A₂A receptor define ligand efficacy. Mol Pharmacol (2013) 0.89
Label-free drug discovery. Front Pharmacol (2014) 0.85
Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time. Naunyn Schmiedebergs Arch Pharmacol (2013) 0.84
Molecular docking screening using agonist-bound GPCR structures: probing the A2A adenosine receptor. J Chem Inf Model (2015) 0.83
Computational analysis and predictive modeling of polymorph descriptors. Chem Cent J (2013) 0.81
Label-free cell phenotypic assessment of the biased agonism and efficacy of agonists at the endogenous muscarinic M3 receptors. J Pharmacol Toxicol Methods (2013) 0.78
Molecular mechanism of allosteric modulation at GPCRs: insight from a binding kinetics study at the human A1 adenosine receptor. Br J Pharmacol (2014) 0.77
Kv 11.1 (hERG)-induced cardiotoxicity: a molecular insight from a binding kinetics study of prototypical Kv 11.1 (hERG) inhibitors. Br J Pharmacol (2014) 0.77
Structure-Based Design of Reactive Nucleosides for Site-Specific Modification of the A2A Adenosine Receptor. ACS Med Chem Lett (2014) 0.76
TSPO ligand residence time: a new parameter to predict compound neurosteroidogenic efficacy. Sci Rep (2016) 0.76
Characterization of 12 GnRH peptide agonists - a kinetic perspective. Br J Pharmacol (2015) 0.75
Structure-Activity Relationships of the Sustained Effects of Adenosine A2A Receptor Agonists Driven by Slow Dissociation Kinetics. Mol Pharmacol (2016) 0.75
Mass spectrometry-based ligand binding assays on adenosine A1 and A2A receptors. Purinergic Signal (2015) 0.75
Structure-Activity Analysis of Biased Agonism at the Human Adenosine A3 Receptor. Mol Pharmacol (2016) 0.75
Scintillation proximity assay (SPA) as a new approach to determine a ligand's kinetic profile. A case in point for the adenosine A1 receptor. Purinergic Signal (2015) 0.75
A kinetic view of GPCR allostery and biased agonism. Nat Chem Biol (2017) 0.75
Measurement of protein using bicinchoninic acid. Anal Biochem (1985) 74.03
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol (1973) 47.81
The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science (2008) 11.74
International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev (2001) 9.90
Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci (1983) 6.89
Structure of an agonist-bound human A2A adenosine receptor. Science (2011) 6.21
Adenosine receptors as therapeutic targets. Nat Rev Drug Discov (2006) 6.15
Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists. Methods Biochem Anal (2005) 5.37
Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature (2011) 4.60
Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov (2006) 4.56
[3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. J Pharmacol Exp Ther (1989) 4.18
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. Pharmacol Rev (2011) 4.16
Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry (2008) 2.47
Real-time monitoring of morphological changes in living cells by electronic cell sensor arrays: an approach to study G protein-coupled receptors. Anal Chem (2006) 2.32
Biochemical mechanisms of drug action: what does it take for success? Nat Rev Drug Discov (2004) 1.74
Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists. J Med Chem (2003) 1.70
The kinetics of competitive radioligand binding predicted by the law of mass action. Mol Pharmacol (1984) 1.69
PD 115,199: an antagonist ligand for adenosine A2 receptors. Naunyn Schmiedebergs Arch Pharmacol (1987) 1.48
The application of cell-based label-free technology in drug discovery. Biotechnol J (2008) 1.41
Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br J Pharmacol (2010) 1.41
Evaluating cellular impedance assays for detection of GPCR pleiotropic signaling and functional selectivity. J Biomol Screen (2009) 1.30
The importance of drug-target residence time. Curr Opin Drug Discov Devel (2009) 1.24
Emerging adenosine receptor agonists. Expert Opin Emerg Drugs (2007) 1.19
Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor. Br J Pharmacol (2006) 1.17
Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Mol Pharmacol (2009) 1.16
New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine. J Med Chem (2004) 1.12
The adenosine A2A receptor interacts with the actin-binding protein alpha-actinin. J Biol Chem (2003) 1.03
Slow antagonist dissociation and long-lasting in vivo receptor protection. Trends Pharmacol Sci (2006) 1.00
2,5'-Disubstituted adenosine derivatives: evaluation of selectivity and efficacy for the adenosine A(1), A(2A), and A(3) receptor. J Med Chem (2002) 1.00
SAR of a series of inhaled A(2A) agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data. Bioorg Med Chem Lett (2009) 0.99
(-)-S-[3H]CGP-12177 and its use to determine the rate constants of unlabeled beta-adrenergic antagonists. Proc Natl Acad Sci U S A (1985) 0.97
Binding thermodynamics at A1 and A2A adenosine receptors. Life Sci (1996) 0.95
Impedance-based cellular assay technologies: recent advances, future promise. Curr Opin Pharmacol (2007) 0.94
From cradle to twilight: the carboxyl terminus directs the fate of the A(2A)-adenosine receptor. Biochim Biophys Acta (2010) 0.94
Functional selectivity of adenosine receptor ligands. Purinergic Signal (2011) 0.93
Binding of [3H]MSX-2 (3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine) to rat striatal membranes--a new, selective antagonist radioligand for A(2A) adenosine receptors. Eur J Pharm Sci (2000) 0.92
Binding of [3H]KF17837S, a selective adenosine A2 receptor antagonist, to rat brain membranes. Mol Pharmacol (1994) 0.91
Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261. Br J Pharmacol (1997) 0.88
The protease-activated receptor-2-specific agonists 2-aminothiazol-4-yl-LIGRL-NH2 and 6-aminonicotinyl-LIGRL-NH2 stimulate multiple signaling pathways to induce physiological responses in vitro and in vivo. J Biol Chem (2011) 0.88
Kinetic analysis of the interactions of agonists and antagonists with beta adrenergic receptors. J Pharmacol Exp Ther (1986) 0.87
Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes. Br J Pharmacol (1996) 0.86
2,8-Disubstituted adenosine derivatives as partial agonists for the adenosine A2A receptor. Bioorg Med Chem (2003) 0.86
Evaluation of cannabinoid receptor 2 and metabotropic glutamate receptor 1 functional responses using a cell impedance-based technology. J Biomol Screen (2010) 0.84
Inhaled adenosine A(2A) receptor agonists for the treatment of chronic obstructive pulmonary disease. Bioorg Med Chem Lett (2008) 0.84
Partial agonism at the human alpha(2A)-autoreceptor: role of binding duration. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.80
Real-time cellular impedance measurements detect Ca(2+) channel-dependent oscillations of morphology in human H295R adrenoma cells. Biochim Biophys Acta (2011) 0.79
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. Pharmacol Rev (2011) 4.16
Structural basis for allosteric regulation of GPCRs by sodium ions. Science (2012) 3.40
2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem (2008) 1.87
New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine. J Med Chem (2004) 1.12
Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives. Mol Pharmacol (2002) 1.11
International Union of Basic and Clinical Pharmacology. LXXXII: Nomenclature and Classification of Hydroxy-carboxylic Acid Receptors (GPR81, GPR109A, and GPR109B). Pharmacol Rev (2011) 1.11
Drug-target residence time--a case for G protein-coupled receptors. Med Res Rev (2014) 1.06
2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem (2004) 1.02
Tracing evolutionary pressure. Bioinformatics (2008) 0.96
The role of a sodium ion binding site in the allosteric modulation of the A(2A) adenosine G protein-coupled receptor. Structure (2013) 0.95
Differential allosteric modulation by amiloride analogues of agonist and antagonist binding at A(1) and A(3) adenosine receptors. Biochem Pharmacol (2003) 0.95
Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor. J Chem Inf Model (2013) 0.92
False positives in a reporter gene assay: identification and synthesis of substituted N-pyridin-2-ylbenzamides as competitive inhibitors of firefly luciferase. J Med Chem (2008) 0.91
Dual-point competition association assay: a fast and high-throughput kinetic screening method for assessing ligand-receptor binding kinetics. J Biomol Screen (2012) 0.90
Identifying novel adenosine receptor ligands by simultaneous proteochemometric modeling of rat and human bioactivity data. J Med Chem (2012) 0.90
Synthesis and evaluation of homo-bivalent GnRHR ligands. Bioorg Med Chem (2007) 0.90
Structure-kinetic relationships--an overlooked parameter in hit-to-lead optimization: a case of cyclopentylamines as chemokine receptor 2 antagonists. J Med Chem (2013) 0.87
A series of 2,4-disubstituted quinolines as a new class of allosteric enhancers of the adenosine A3 receptor. J Med Chem (2009) 0.86
Random mutagenesis of the human adenosine A2B receptor followed by growth selection in yeast. Identification of constitutively active and gain of function mutations. Mol Pharmacol (2004) 0.86
Synthesis and biological evaluation of 2,3,5-substituted [1,2,4]thiadiazoles as allosteric modulators of adenosine receptors. J Med Chem (2004) 0.86
Selecting an optimal number of binding site waters to improve virtual screening enrichments against the adenosine A2A receptor. J Chem Inf Model (2014) 0.84
Substructure-based virtual screening for adenosine A2A receptor ligands. ChemMedChem (2011) 0.84
Fragment screening of GPCRs using biophysical methods: identification of ligands of the adenosine A(2A) receptor with novel biological activity. ACS Chem Biol (2012) 0.84
The endocannabinoid 2-arachidonylglycerol is a negative allosteric modulator of the human A3 adenosine receptor. Biochem Pharmacol (2009) 0.84
Synthesis and biological evaluation of 2-aminothiazoles and their amide derivatives on human adenosine receptors. Lack of effect of 2-aminothiazoles as allosteric enhancers. Bioorg Med Chem (2005) 0.84
Agonists for the adenosine A1 receptor with tunable residence time. A Case for nonribose 4-amino-6-aryl-5-cyano-2-thiopyrimidines. J Med Chem (2014) 0.83
2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem (2006) 0.82
Multiple binding sites for small-molecule antagonists at the CC chemokine receptor 2. Mol Pharmacol (2013) 0.82
A novel nonribose agonist, LUF5834, engages residues that are distinct from those of adenosine-like ligands to activate the adenosine A(2a) receptor. Mol Pharmacol (2011) 0.82
A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor. J Med Chem (2005) 0.82
Label-free impedance responses of endogenous and synthetic chemokine receptor CXCR3 agonists correlate with Gi-protein pathway activation. Biochem Biophys Res Commun (2012) 0.81
A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines. Bioorg Med Chem (2008) 0.81
Understanding of molecular substructures that contribute to hERG K+ channel blockade: synthesis and biological evaluation of E-4031 analogues. ChemMedChem (2011) 0.80
Modulation of agonist responses at the A(1) adenosine receptor by an irreversible antagonist, receptor-G protein uncoupling and by the G protein activation state. Biochem Pharmacol (2002) 0.80
Allosteric modulation, thermodynamics and binding to wild-type and mutant (T277A) adenosine A1 receptors of LUF5831, a novel nonadenosine-like agonist. Br J Pharmacol (2006) 0.80
Binding kinetics of ZM241385 derivatives at the human adenosine A2A receptor. ChemMedChem (2014) 0.79
Strategies to reduce HERG K+ channel blockade. Exploring heteroaromaticity and rigidity in novel pyridine analogues of dofetilide. J Med Chem (2013) 0.79
Discovery of selective luteinizing hormone receptor agonists using the bivalent ligand method. ChemMedChem (2009) 0.79
Substructure mining of GPCR ligands reveals activity-class specific functional groups in an unbiased manner. J Chem Inf Model (2009) 0.79
Putative role of the adenosine A(3) receptor in the antiproliferative action of N (6)-(2-isopentenyl)adenosine. Purinergic Signal (2011) 0.79
N6-cyclopentyl-2-(3-phenylaminocarbonyltriazene-1-yl)adenosine (TCPA), a very selective agonist with high affinity for the human adenosine A1 receptor. J Med Chem (2003) 0.78
2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem (2007) 0.78
Molecular mechanism of allosteric modulation at GPCRs: insight from a binding kinetics study at the human A1 adenosine receptor. Br J Pharmacol (2014) 0.77
Synthesis and evaluation of homodimeric GnRHR antagonists having a rigid bis-propargylated benzene core. Bioorg Med Chem (2008) 0.77
Inhibition of nucleoside transport proteins by C8-alkylamine-substituted purines. J Med Chem (2005) 0.77
Synthesis, binding affinity and structure-activity relationships of novel, selective and dual targeting CCR2 and CCR5 receptor antagonists. Org Biomol Chem (2015) 0.76
Data-driven approaches used for compound library design, hit triage and bioactivity modeling in high-throughput screening. Brief Bioinform (2016) 0.76
Allosteric approaches to GPCR drug discovery. Drug Discov Today Technol (2013) 0.75
Temperature dependence of the affinity enhancement of selective adenosine A1 receptor agonism: a thermodynamic analysis. Eur J Pharmacol (2002) 0.75
Inhibition of nucleoside transport by new analogues of 4-nitrobenzylthioinosine: replacement of the ribose moiety by substituted benzyl groups. J Med Chem (2004) 0.75
Low efficacy adenosine A1 agonists inhibit striatal acetylcholine release in rats improving central selectivity of action. Neurosci Lett (2003) 0.75
5'-Deoxy congeners of 9-(3-amido-3-deoxy-beta-D-xylofuranosyl)-N(6)-cyclopentyladenine: new adenosine A(1) receptor antagonists and inverse agonists. J Med Chem (2002) 0.75
Synthesis and biological evaluation of novel allosteric enhancers of the A1 adenosine receptor based on 2-amino-3-(4'-chlorobenzoyl)-4-substituted-5-arylethynyl thiophene. J Med Chem (2014) 0.75
Multi-objective evolutionary design of adenosine receptor ligands. J Chem Inf Model (2012) 0.75
Inhibition of nucleoside transport by new analogues of nitrobenzylthioinosine. Bioorg Med Chem (2003) 0.75